Jocelyn Ulrich Jocelyn Ulrich, MPH, is Deputy Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, she is responsible for developing legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, the R&D process, the value of innovation, and other issue areas impacting the environment for innovation. In addition to her experience at PhRMA she has over 15 years of experience in the pharmaceutical industry at Pfizer, Human Genome Sciences, and EMD Serono in roles in clinical research management, investigator-initiated and collaborative research, and global policy and corporate affairs. Jocelyn holds an MPH in global health policy and management from New York University.
Recent Posts
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
By Jocelyn Ulrich | February 22, 2021
As America’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen...
Read More
New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem
By Jocelyn Ulrich | September 16, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...
Read More
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
By Jocelyn Ulrich | July 13, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...
Read More
Clinical Trials Q&A: A patient’s perspective
By Jocelyn Ulrich | May 4, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Clinical Trials Q&A: Examining clinical trial design
By Jocelyn Ulrich | April 12, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Clinical Trials Q&A: Income disparities
By Jocelyn Ulrich | March 14, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
BMJ clinical trial report misleading
By Jocelyn Ulrich | November 16, 2015
Biopharmaceutical companies are committed to enhancing the transparency of their research in a responsible manner. To demonstrate their commitment, in July 2013 PhRMA joined with the European...
Read More
Clinical Trials Q&A: Improving the recruitment process by listening to patients
By Jocelyn Ulrich | October 22, 2015
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today's challenges and opportunities. The Catalyst welcomes guest...
Read More
Clinical Trials Q&A : How does collaboration increase clinical trial awareness and access?
By Jocelyn Ulrich | October 20, 2015
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today's challenges and opportunities. The Catalyst welcomes guest...
Read More
Introducing clinical research participation to the everyday person
By Jocelyn Ulrich | October 15, 2015
Clinical trials involve many different people and institutions coming together to better understand disease, biology and the impact of potential medicines. Carefully conducted clinical trials are...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
